Advanced in Hodgkin Lymphoma

Dr. Jeremy M. Pantin

Hematology Oncology | Hematology | Oncology
Tristar Bone Marrow Transplant, LLC
2300 Patterson St, 
Nashville, TN 
Accepting New Patients
22 Years of Experience
Advanced in Hodgkin Lymphoma
Tristar Bone Marrow Transplant, LLC
2300 Patterson St, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeremy Pantin is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Pantin has been practicing medicine for over 22 years and is rated as an Advanced provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Pantin is currently accepting new patients.

His clinical research consists of co-authoring 25 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Hodgkin Lymphoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in GA
Hospital Affiliations
Tristar Centennial Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

TRISTAR BONE MARROW TRANSPLANT, LLC
2300 Patterson St, Nashville, TN 37203
Other Locations
TRISTAR BONE MARROW TRANSPLANT, LLC
1325 Andrea St, Suite 201, Bowling Green, KY 42104
TRISTAR BONE MARROW TRANSPLANT, LLC
2410 Patterson St, Suite 500, Nashville, TN 37203
TRISTAR BONE MARROW TRANSPLANT, LLC
322 Hospital Blvd, Jackson, TN 38305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Biological
Study Drugs: Cyclophosphamide, Fludarabine, CD19-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Other, Biological
Study Drug: AB-205
Study Phase: Phase 3
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Biological
Study Drug: Allogeneic NKG2D-Targeted CAR-Natural Killer T Cells
Study Phase: Phase 1
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
Enrollment Status: Completed
Publish Date: December 05, 2023
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
An Open-label Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute Graft Versus Host Disease (aGVHD)
An Open-label Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute Graft Versus Host Disease (aGVHD)
Enrollment Status: Terminated
Publish Date: August 28, 2023
Intervention Type: Drug
Study Phase: Phase 1
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: June 18, 2023
Intervention Type: Biological
Study Drug: Mana 312
Study Phase: Phase 1
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

25 Total Publications

Cryopreserved organ donor bone marrow achieves robust engraftment and chimerism in mismatched allogeneic transplantation.
Cryopreserved organ donor bone marrow achieves robust engraftment and chimerism in mismatched allogeneic transplantation.
Journal: Cytotherapy
Published: August 27, 2025
Similar Doctors
Distinguished in Hodgkin Lymphoma
Dr. Nishitha M. Reddy
Hematology Oncology | Oncology | Hematology
Distinguished in Hodgkin Lymphoma
Dr. Nishitha M. Reddy
Hematology Oncology | Oncology | Hematology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (1.0 miles away)
615-322-3000
Languages Spoken:
English, Hindi, Spanish, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Nishitha Reddy is a Hematologist Oncology specialist and an Oncologist in Nashville, Tennessee. Dr. Reddy is rated as a Distinguished provider by MediFind in the treatment of Hodgkin Lymphoma. Her top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration. Dr. Reddy is currently accepting new patients.

Distinguished in Hodgkin Lymphoma
Dr. Jamie B. Jarboe
Hematology Oncology | Hematology | Oncology
Distinguished in Hodgkin Lymphoma
Dr. Jamie B. Jarboe
Hematology Oncology | Hematology | Oncology

Commonwealth Health Corporation, Inc.

350 Park St, Suite 106, 
Bowling Green, KY 
 (61.8 miles away)
270-796-2557
Languages Spoken:
English
See accepted insurances

Jamie Jarboe is a Hematologist Oncology specialist and a Hematologist in Bowling Green, Kentucky. Dr. Jarboe is rated as a Distinguished provider by MediFind in the treatment of Hodgkin Lymphoma. Her top areas of expertise are Pleuropulmonary Blastoma, Hodgkin Lymphoma, Lung Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Advanced in Hodgkin Lymphoma
Dr. David S. Morgan
Oncology | Hematology Oncology
Advanced in Hodgkin Lymphoma
Dr. David S. Morgan
Oncology | Hematology Oncology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (1.0 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Morgan is an Oncologist and a Hematologist Oncology provider in Nashville, Tennessee. Dr. Morgan is rated as a Distinguished provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration. Dr. Morgan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pantin's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 19 Advanced Conditions
    View All 52 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile